N4 Pharma presents Nuvec in Japan

N4 Pharma will present its Nuvec in a meeting with japanese companies in February. The UK pharmaceutical company will be funded from Innovate UK, the UK’s innovation agency, to attend the Global Business Accelerator Programme Cell and Gene Therapy Visit to Japan.

According to N4 Pharma’s announcement from Wednesday, it will be among a group of innovative UK companies operating in the cell and gene therapy sector that the UK’s innovation agency will fund for visiting Japan in February. For the Cell and Gene Therapy Matchmaking event and Medical Japan 2018, N4 Pharma will also get pre- and post-visit support to help follow up on meetings held during the events.

Nigel Theobald, CEO of N4 Pharma, said N4 will be presenting Nuvec to relevant companies in Japan.

“With the Asia-Pacific DNA vaccine market forecast to grow at a CAGR of 45.85% through to 2025, driven by factors such as a growing population with unmet medical needs and increasing awareness regarding the advantages of vaccines, Japan represents an exciting potential future market for N4 Pharma’s offerings,” said  Theobald.